R. G. Will and J. W. Ironside, Sporadic and infectious human prion diseases. Cold Spring Harbor perspectives in medicine, vol.7, 2017.

S. J. Collins, P. Sanchez-juan, C. L. Masters, G. M. Klug, C. Van-duijn et al., Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease, Brain J Neurol, vol.129, pp.2278-2287, 2006.

P. Brown, F. Cathala, R. F. Raubertas, D. C. Gajdusek, and P. Castaigne, The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature, Neurology, vol.37, issue.6, pp.895-904, 1987.

R. C. Holman, E. D. Belay, K. Y. Christensen, R. A. Maddox, A. M. Minino et al., Human prion diseases in the United States, PLoS One, vol.5, issue.1, p.8521, 2010.

B. Van-everbroeck, I. Dobbeleir, M. De-waele, D. Deyn, P. Martin et al., Differential diagnosis of 201 possible CreutzfeldtJakob disease patients, J Neurol, vol.251, issue.3, pp.298-304, 2004.

R. W. Paterson, C. C. Torres-chae, A. L. Kuo, T. Ando, E. A. Nguyen et al., Differential diagnosis of Jakob-Creutzfeldt disease, Arch Neurol, vol.69, issue.12, pp.1578-1582, 2012.

S. Jayaratnam, A. K. Khoo, and D. Basic, Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid, Age Ageing, vol.37, issue.4, pp.467-469, 2008.

S. Reinwald, I. M. Westner, and N. Niedermaier, Rapidly progressive Alzheimer's disease mimicking Creutzfeldt-Jakob disease, J Neurol, vol.251, issue.8, pp.1020-1022, 2004.

, Mol Neurobiol

K. Stoeck, P. Sanchez-juan, J. Gawinecka, A. Green, A. Ladogana et al., Cerebrospinal fluid biomarker supported diagnosis of CreutzfeldtJakob disease and rapid dementias: a longitudinal multicentre study over 10 years, Brain J Neurol, vol.135, pp.3051-3061, 2012.

G. Hsich, K. Kenney, C. J. Gibbs, K. H. Lee, and M. G. Harrington, The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies, N Engl J Med, vol.335, issue.13, pp.924-930, 1996.

I. Zerr, M. Bodemer, O. Gefeller, M. Otto, S. Poser et al., Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease, Ann Neurol, vol.43, issue.1, pp.32-40, 1998.

S. Collins, A. Boyd, A. Fletcher, M. Gonzales, C. A. Mclean et al., Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid, Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia, vol.7, issue.3, pp.203-208, 2000.

, WHO manual for surveillance of human transmissible spongiform encephalopathies, including variant CreutzfeldtJakob disease, World Health Organization, 2003.

Y. Shiga, K. Miyazawa, S. Sato, R. Fukushima, S. Shibuya et al., Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease, Neurology, vol.63, issue.3, pp.443-449, 2004.

I. Zerr, K. Kallenberg, D. M. Summers, C. Romero, A. Taratuto et al., Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease, Brain J Neurol, vol.132, pp.2659-2668, 2009.

R. Sanchez-valle, A. Saiz, and F. Graus, protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease, Neurosci Lett, vol.320, issue.1-2, pp.69-72, 2002.

T. Shimada, A. E. Fournier, and K. Yamagata, Neuroprotective function of 14-3-3 proteins in neurodegeneration, Biomed Res Int, p.564534, 2013.

Y. Shiga, H. Wakabayashi, K. Miyazawa, H. Kido, and Y. Itoyama, protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages, Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia, vol.13, issue.6, pp.661-665, 2006.

J. Wiltfang, M. Otto, H. C. Baxter, M. Bodemer, P. Steinacker et al., Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurochem, vol.73, issue.6, pp.2485-2490, 1999.

K. Satoh, M. Tobiume, Y. Matsui, K. Mutsukura, N. Nishida et al., Establishment of a standard 14-33 protein assay of cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease, Laboratory investigation; a journal of technical methods and pathology, vol.90, issue.11, pp.1637-1644, 2010.

A. J. Green, E. J. Thompson, G. E. Stewart, M. Zeidler, J. M. Mckenzie et al., Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiatry, vol.70, issue.6, pp.744-748, 2001.

A. Koller and H. Watzig, Precision and variance components in quantitative gel electrophoresis, Electrophoresis, vol.26, issue.12, pp.2470-2475, 2005.

M. Schmitz, E. Ebert, K. Stoeck, A. Karch, S. Collins et al., Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic, Mol Neurobiol, vol.53, issue.4, pp.2189-2199, 2016.

J. P. Brandel, L. Peckeu, and S. Haik, The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide. Transfusion clinique et biologique: journal de la Societe francaise de transfusion sanguine, vol.20, pp.395-397, 2013.

P. Giraud, A. G. Biacabe, G. Chazot, R. Later, O. Joyeux et al., Increased detection of 14-3-3 protein in cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease during the disease course, Eur Neurol, vol.48, issue.4, pp.218-221, 2002.

G. Dimeski, Interference testing, The Clinical biochemist Reviews, vol.29, issue.1, pp.43-48, 2008.

M. Baker, Reproducibility crisis: blame it on the antibodies, Nature, vol.521, issue.7552, pp.274-276, 2015.

N. Chitravas, R. S. Jung, D. M. Kofskey, J. E. Blevins, P. Gambetti et al., Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease, Ann Neurol, vol.70, issue.3, pp.437-444, 2011.

M. D. Geschwind, H. Shu, A. Haman, J. J. Sejvar, and B. L. Miller, Rapidly progressive dementia, Ann Neurol, vol.64, issue.1, pp.97-108, 2008.

I. N. Day and R. J. Thompson, Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 143-3 protein in circulating human blood cells, Clinica chimica acta; international journal of clinical chemistry, vol.136, issue.2-3, pp.219-228, 1984.

T. Muayqil, G. Gronseth, and R. Camicioli, Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology, Neurology, vol.79, issue.14, pp.1499-1506, 2012.

B. R. Van-everbroeck, J. Boons, and P. Cras, [1]-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias, J Neurol Neurosurg Psychiatry, vol.76, issue.1, pp.100-102, 2005.

Y. Matsui, K. Satoh, T. Miyazaki, S. Shirabe, R. Atarashi et al., High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease, BMC Neurol, vol.11, p.120, 2011.

M. J. Leitao, I. Baldeiras, M. R. Almeida, M. H. Ribeiro, A. C. Santos et al., Sporadic CreutzfeldtJakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3gamma assay, Neuroscience, vol.322, pp.398-407, 2016.

J. Satoh, K. Kurohara, M. Yukitake, and Y. Kuroda, The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prionunrelated neurological diseases is expressed constitutively in neurons and glial cells in culture, Eur Neurol, vol.41, issue.4, pp.216-225, 1999.

K. Kenney, C. Brechtel, H. Takahashi, K. Kurohara, P. Anderson et al., An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients, Ann Neurol, vol.48, issue.3, pp.395-398, 2000.

P. Beaudry, P. Cohen, J. P. Brandel, N. Delasnerie-laupretre, S. Richard et al., protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Dement Geriatr Cogn Disord, vol.10, issue.1, pp.40-46, 1999.

M. Riemenschneider, S. Wagenpfeil, H. Vanderstichele, M. Otto, J. Wiltfang et al., Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias, Mol Psychiatry, vol.8, issue.3, pp.343-347, 2003.

T. Kasai, T. Tokuda, R. Ishii, N. Ishigami, Y. Tsuboi et al., Increased alpha-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurol, vol.261, issue.6, pp.1203-1209, 2014.

M. Otto, J. Wiltfang, L. Cepek, M. Neumann, B. Mollenhauer et al., , 2002.

F. Llorens, N. Kruse, A. Karch, M. Schmitz, S. Zafar et al., Validation of alpha-Synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease, Mol Neurobiol, 2017.

A. Dorey, Y. Tholance, A. Vighetto, A. Perret-liaudet, I. Lachman et al., Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease, JAMA neurology, vol.72, issue.3, pp.267-275, 2015.

L. I. Mcguire, A. H. Peden, C. D. Orru, J. M. Wilham, N. E. Appleford et al., Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease, Ann Neurol, vol.72, issue.2, pp.278-285, 2012.

J. Wang, A. Valdez, and Y. Chen, Evaluation of automated Wes system as an analytical and characterization tool to support monoclonal antibody drug product development, J Pharm Biomed Anal, 2016.

N. Padhan, T. E. Nordling, M. Sundstrom, P. Akerud, H. Birgisson et al., High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer, BMC Cancer, vol.16, issue.1, p.683, 2016.

S. Halbgebauer, U. Haussmann, H. Klafki, H. Tumani, J. Wiltfang et al., Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands, Electrophoresis, vol.36, issue.2, pp.355-362, 2015.

G. G. Kovacs, Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine, Int J Mol Sci, vol.17, issue.2, 2016.

, 2% Patient, vol.4, issue.28, p.6

, Development of an automated capillary nano-immunoassay-Simple Western assay-to quantify total TDP43 protein

R. 1. Rabinovici, G. D. Miller, and B. L. , Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management, CNS Drugs, vol.24, issue.5, pp.375-98, 2010.

J. D. Warren, J. D. Rohrer, and M. N. Rossor, Clinical review. Frontotemporal dementia, BMJ, vol.347, 2013.

D. Neary, J. Snowden, and D. Mann, Frontotemporal dementia, Lancet Neurol, vol.4, issue.11, pp.70223-70227, 2005.

M. Grossman, Primary progressive aphasia: clinicopathological correlations, Nat Rev Neurol, vol.6, issue.2, pp.88-97, 2010.

D. J. Irwin, N. J. Cairns, M. Grossman, C. T. Mcmillan, E. B. Lee et al., Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine, Acta Neuropathol, vol.129, issue.4, pp.469-91, 2015.

K. Rascovsky, J. R. Hodges, D. Knopman, M. F. Mendez, J. H. Kramer et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, vol.134, pp.2456-77, 2011.

M. L. Gorno-tempini, A. E. Hillis, S. Weintraub, A. Kertesz, M. Mendez et al., Classification of primary progressive aphasia and its variants, Neurology, vol.76, issue.11, pp.1006-1020, 2011.

M. Neumann, D. M. Sampathu, L. K. Kwong, A. C. Truax, M. C. Micsenyi et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, vol.314, issue.5796, pp.130-133, 2006.

J. Gao, L. Wang, M. L. Huntley, G. Perry, and X. Wang, Pathomechanisms of TDP-43 in neurodegeneration, J Neurochem, 2018.

E. Buratti, TDP-43 post-translational modifications in health and disease, Expert Opin Ther Targets, vol.22, issue.3, pp.279-93, 2018.

F. Geser, D. Prvulovic, O. Dwyer, L. Hardiman, O. Bede et al., On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia, Prog Neurobiol, vol.95, issue.4, pp.649-62, 2011.

G. M. Mckhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, issue.3, pp.263-272, 2011.

H. M. Snyder, M. C. Carrillo, F. Grodstein, K. Henriksen, A. Jeromin et al., Developing novel blood-based biomarkers for Alzheimer's disease, Alzheimers Dement, vol.10, issue.1, pp.109-123, 2014.

L. Riedl, I. R. Mackenzie, H. Forstl, A. Kurz, and J. Diehl-schmid, Frontotemporal lobar degeneration: current perspectives, Neuropsychiatr Dis Treat, vol.10, pp.297-310, 2014.

T. Kasai, T. Tokuda, N. Ishigami, H. Sasayama, P. Foulds et al., Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis, Acta Neuropathol, vol.117, issue.1, pp.55-62, 2009.

P. G. Foulds, Y. Davidson, M. Mishra, D. J. Hobson, K. M. Humphreys et al., Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration, Acta Neuropathol, vol.118, issue.5, pp.647-58, 2009.

E. Feneberg, E. Gray, O. Ansorge, K. Talbot, and M. R. Turner, Towards a TDP-43-based biomarker for ALS and FTLD, Mol Neurobiol, 2018.

G. J. Anderson, C. Mc, and R. T. Kennedy, Western blotting using capillary electrophoresis, Anal Chem, vol.83, issue.4, pp.1350-1355, 2011.

A. J. Hughes and A. E. Herr, Microfluidic Western blotting, Proc Natl Acad Sci U S A, vol.109, issue.52, pp.21450-21455, 2012.

J. Q. Chen, L. M. Wakefield, and D. J. Goldstein, Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics, J Transl Med, vol.13, p.182, 2015.

M. Behari and M. Shrivastava, Role of platelets in neurodegenerative diseases: a universal pathophysiology, Int J Neurosci, vol.123, issue.5, pp.287-99, 2013.

E. M. Wood, D. Falcone, E. Suh, D. J. Irwin, A. S. Chen-plotkin et al., Development and validation of pedigree classification criteria for frontotemporal lobar degeneration, JAMA Neurol, vol.70, issue.11, pp.1411-1418, 2013.

C. Akimoto, A. E. Volk, M. Van-blitterswijk, M. Van-den-broeck, C. S. Leblond et al., A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories, J Med Genet, vol.51, issue.6, pp.419-443, 2014.

J. Goossens, E. Vanmechelen, J. Q. Trojanowski, V. M. Lee, C. Van-broeckhoven et al., TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies, Acta Neuropathol Commun, vol.3, p.15, 2015.

G. M. Nelson, J. M. Guynn, and B. N. Chorley, J Vis Exp, issue.127, 2017.

A. Fourier,

A. Alegria-schaffer, A. Lodge, and K. Vattem, Performing and optimizing Western blots with an emphasis on chemiluminescent detection, Methods Enzymol, vol.463, issue.09, pp.63033-63033, 2009.

A. Rath, M. Glibowicka, V. G. Nadeau, G. Chen, and C. M. Deber, Detergent binding explains anomalous SDS-PAGE migration of membrane proteins, Proc Natl Acad Sci U S A, vol.106, issue.6, pp.1760-1765, 2009.

, R&D systems a biotechne brand. Human/Mouse/Rat TDP-43/ TARDBP Antibody-Monoclonal Mouse IgG2A Clone # 671834-Catalog Number: MAB7778

P. Steinacker, C. Hendrich, A. D. Sperfeld, J. S. , V. Arnim et al., TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Arch Neurol, vol.65, issue.11, pp.1481-1488, 2008.

S. J. Charette, H. Lambert, P. J. Nadeau, and J. Landry, Protein quantification by chemiluminescent Western blotting: elimination of the antibody factor by dilution series and calibration curve, J Immunol Methods, vol.353, issue.1-2, pp.148-50, 2010.

A. Fourier, A. Dorey, A. Perret-liaudet, and I. Quadrio, Detection of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease patients using a new automated capillary Western assay, Mol Neurobiol, 2017.

N. Mattsson, U. Andreasson, S. Persson, M. C. Carrillo, S. Collins et al., CSF biomarker variability in the Alzheimer's Association quality control program, Alzheimers Dement, vol.9, issue.3, pp.251-61, 2013.

B. Callister, J. Pickering-brown, and S. M. , Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS, Exp Neurol, vol.262, pp.84-90, 2014.